MBX Biosciences, Inc. Common Stock

MBX

$61.42

+0.87%

N/A+$0.53

Healthcare

Biotechnology

NASDAQ

Active Trading

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic ...

Fundamental Analysis of MBX

Key Strengths

Strong clinical data for lead candidate canvuparatide in hypoparathyroidism, with 57% responder rate in one-year study

Early-stage obesity candidate MBX-4291 shows promising efficacy, tapping into a massive market

Risk Factors

No approved products or revenue; company is entirely dependent on pipeline success

High cash burn with negative operating cash flow of -$82.5M TTM, requiring potential future dilutive financing

Profitability

Net Margin0.00%

Operating Margin0.00%

Valuation

P/E Ratio-25.59x

Current Ratio18.08

Efficiency

ROE-26.01%

ROA-23.93%

Fundamental Analysis of MBX

MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders. With no approved products or revenue, the company's valuation is entirely dependent on its pipeline's clinical progress and commercial potential. The lead candidate, canvuparatide (MBX 2109), a parathyroid hormone prodrug for chronic hypoparathyroidism, has shown encouraging Phase 2 data, including a 57% responder rate in a one-year extension study, fueling optimism despite the competitive landscape. Additionally, MBX-4291, a GLP-1/GIP co-agonist prodrug for obesity, has generated promising early data, positioning the company in the high-growth obesity market. However, the company faces significant risks: it has no revenue, substantial R&D expenses (with operating cash flow of -$82.5M TTM), a high cash burn rate, and relies on finite cash reserves ($409M tangible assets) to fund trials. The stock has surged over 370% in the past year, reflecting speculative optimism, but fundamentals remain unproven. The financial metrics (e.g., negative margins, ROE, ROA) are expected of a pre-revenue biotech, with no near-term profitability. The company's strong balance sheet (current ratio 18.08, negligible debt) provides a runway into 2027, but clinical trial failures or regulatory setbacks would severely impair value. Long-term success hinges on advancing the pipeline, achieving regulatory milestones, and ultimately commercializing therapies in competitive markets.

Key Strengths of MBX

Strong clinical data for lead candidate canvuparatide in hypoparathyroidism, with 57% responder rate in one-year study
Early-stage obesity candidate MBX-4291 shows promising efficacy, tapping into a massive market
Proprietary prodrug platform (PEP) enables differentiated peptide therapies with potentially improved dosing
Robust financial position: $409M in tangible assets, current ratio of 18.08, minimal debt, and cash runway expected to last several years
Recent reclassification into Russell growth indexes, broadening institutional investor base and improving liquidity
Experienced management team with prior successes in biotech commercialization
Low beta (0.10) suggests reduced market correlation, though this reflects untested fundamentals
Multiple pipeline assets beyond lead candidates, including MBX-1416 for post-bariatric hypoglycemia, diversifying development risk

Risk Factors of MBX

No approved products or revenue; company is entirely dependent on pipeline success
High cash burn with negative operating cash flow of -$82.5M TTM, requiring potential future dilutive financing
Clinical trial failure risk: late-stage trials may not replicate earlier results or may face FDA setbacks
Intense competition from established players in hypoparathyroidism (e.g., Ascendis Pharma) and obesity (e.g., Novo Nordisk, Eli Lilly)
Regulatory uncertainty: upcoming pivotal trials may face design or endpoint challenges
Stock volatility: shares surged over 370% in a year, suggesting speculative pricing and potential for sharp corrections
Dependence on single lead asset for near-term value creation; pipeline diversity is limited in later-stage assets
Macroeconomic and geopolitical risks could affect market sentiment and capital availability

Market Cap vs Revenue & Earnings

Earnings

n/a

Revenue

n/a

Market cap

$2.92B

-25.6x

P/E Ratio

0.0x

P/S Ratio

Earnings & Revenue

Last Reportedn/a

Earnings per share (EPS)n/a

Gross Margin0.00%

Net Profit Margin0.00%

Debt/Equity Ratio0.01

Profitability Bridge (Current vs YoY)

How gross, operating and net margins shifted versus last year.

Revenue / Net Income / FCF History (USD B)

Growth Signals of MBX

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Revenue	—	—	—	—	Flat
Diluted EPS	—	—	—	—	Flat
Free Cash Flow	—	—	—	—	Flat

Profitability of MBX

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Net Margin	—	0.00%	—	—	Flat
Operating Margin	—	0.00%	—	—	Flat
ROE	—	—	—	—	Flat

Financial Health of MBX

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Current Ratio	—	18.084	—	—	Flat
Quick Ratio	—	18.084	—	—	Flat
Debt / Equity	—	0.008	—	—	Flat

Valuation of MBX

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
P/E	—	-17.69x	—	—	Flat
P/B	—	6.43x	—	—	Flat

Supply Chain of MBX

RELATIONS

Upstream

Bachem Holding AGSWX:BANBPolyPeptide Group AGSWX:PPGNCordenPharma GmbHThermo Fisher Scientific Inc. (Patheon)NYSE:TMO Charles River Laboratories International, Inc.NYSE:CRL IQVIA Holdings Inc.NYSE:IQV ICON plcNASDAQ:ICLRIndiana University Research and Technology Corporation (IURTC)Merck KGaA (EMD Millipore)XETRA:MRKSigma-Aldrich (Merck KGaA / MilliporeSigma)XETRA:MRK

Downstream

Hypoparathyroidism Patient Population (Target End-Market)Post-Bariatric Hypoglycemia Patient Population (Target End-Market)Obesity/Metabolic Patient Population (Target End-Market)Ascendis Pharma A/SNASDAQ:ASND AstraZeneca PLCNASDAQ:AZNPotential Future Specialty Pharmacy Partners (e.g., CVS Specialty, Walgreens, Accredo)

Proxies

Ascendis Pharma A/SNASDAQ:ASNDBachem Holding AGSWX:BANBBridgeBio Pharma, Inc.NASDAQ:BBIO Rhythm Pharmaceuticals, Inc.NASDAQ:RYTM

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer